ArticleZeitschrift fur Rheumatologie2017
[Shared decision making even for complex systemic autoimmune diseases such as Systemic Lupus Erythematosus (SLE)?]
Article in Zeitschrift fur Rheumatologie, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- The patient's perspective: are quality of life and disease burden a possible treatment target in systemic lupus erythematosus?Rheumatology (Oxford, England) · 2020Review
- [State of the art: systemic lupus erythematosus].Zeitschrift fur Rheumatologie · 2019Review
Corrections and comments
- Erratum issued
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThe treatment of systemic autoimmune diseases, such as systemic lupus erythematosus (SLE) is an enormous challenge for all involved due to the complexity. This study investigated whether shared decision making (SDM) can advantageously be implemented in such a situation.
methodTo answer this question qualitative group surveys were carried out with rheumatologists according to the standardized method of K&P Psychodrama®. A total of 41 German rheumatologists who had been invited by GlaxoSmithKline (GSK) Germany participated in 2 meetings over a complete day in 2012 and 2013 as well as 2 half-day meetings in 2013, which were carried out by K&A BrandResearch.
resultsIn general rheumatologists were appreciative of their discipline because of the broadly spread field of work, the possibility to "tinker" and the increasing spectrum of effective forms of therapy. Negative points were the increasing amount of work, particularly due to increasing bureaucratic processes, demanding and unreasonable patients. These stressful situations were compensated by treatment of indications that can easily be diagnosed and treated; however, this is contrasted by indications which are insufficiently palpable for patients and physicians alike and this includes SLE. Fear is at the forefront of the interaction, initially by the patient and during the course of treatment ultimately by the physician. In this context, a further fear factor between both parties is the medications that are available for other diseases as support for physician and patient. The necessary emotional distancing of the physician is achieved by a switch to the purely professional level. Personal emotions are depressed by avoidance of empathy.
conclusionThe rheumatologists in this study principally showed excellent prerequisites for SDM; however, for illnesses such as SLE there is a clear need for action on the part of physicians before SDM can be advantageous for affected patients.
Indexed as
Identifiers
27644956What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.